CY1122332T1 - Ανιχνευση και ποσοτικος προσδιορισμος dna ελευθερου κυτταρων δοτη στο κυκλοφοριακο συστημα ληπτων μεταμοσχευσης οργανων - Google Patents

Ανιχνευση και ποσοτικος προσδιορισμος dna ελευθερου κυτταρων δοτη στο κυκλοφοριακο συστημα ληπτων μεταμοσχευσης οργανων

Info

Publication number
CY1122332T1
CY1122332T1 CY20191100106T CY191100106T CY1122332T1 CY 1122332 T1 CY1122332 T1 CY 1122332T1 CY 20191100106 T CY20191100106 T CY 20191100106T CY 191100106 T CY191100106 T CY 191100106T CY 1122332 T1 CY1122332 T1 CY 1122332T1
Authority
CY
Cyprus
Prior art keywords
detection
circulatory system
organ transplant
quantification
donor cell
Prior art date
Application number
CY20191100106T
Other languages
Greek (el)
English (en)
Inventor
Ekkehard Schutz
Julia Beck
Original Assignee
Chronix Biomedical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51989530&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122332(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chronix Biomedical filed Critical Chronix Biomedical
Publication of CY1122332T1 publication Critical patent/CY1122332T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • G01N2800/245Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Transplanting Machines (AREA)
CY20191100106T 2013-05-29 2019-01-24 Ανιχνευση και ποσοτικος προσδιορισμος dna ελευθερου κυτταρων δοτη στο κυκλοφοριακο συστημα ληπτων μεταμοσχευσης οργανων CY1122332T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361828553P 2013-05-29 2013-05-29
PCT/US2014/040055 WO2014194113A2 (en) 2013-05-29 2014-05-29 Detection and quantification of donor cell-free dna in the circulation of organ transplant recipients

Publications (1)

Publication Number Publication Date
CY1122332T1 true CY1122332T1 (el) 2021-01-27

Family

ID=51989530

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100106T CY1122332T1 (el) 2013-05-29 2019-01-24 Ανιχνευση και ποσοτικος προσδιορισμος dna ελευθερου κυτταρων δοτη στο κυκλοφοριακο συστημα ληπτων μεταμοσχευσης οργανων

Country Status (12)

Country Link
US (3) US20160115541A1 (de)
EP (1) EP3004388B2 (de)
CY (1) CY1122332T1 (de)
DK (1) DK3004388T4 (de)
ES (1) ES2704682T5 (de)
HR (1) HRP20190209T4 (de)
HU (1) HUE041935T2 (de)
LT (1) LT3004388T (de)
PL (1) PL3004388T5 (de)
PT (1) PT3004388T (de)
SI (1) SI3004388T2 (de)
WO (1) WO2014194113A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
CA3037126C (en) 2010-05-18 2023-09-12 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ, インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
AU2013249012B2 (en) 2012-04-19 2019-03-28 The Medical College Of Wisconsin, Inc. Highly sensitive surveillance using detection of cell free DNA
EP3117012B1 (de) 2014-03-14 2019-02-20 CareDx, Inc. Verfahren zur überwachung immunsuppressiver therapien in einem transplantatempfänger
EP3134541B1 (de) 2014-04-21 2020-08-19 Natera, Inc. Nachweis von ploidien in chromosomalen segmenten in krebs
EP4358097A1 (de) 2014-07-25 2024-04-24 University of Washington Verfahren zur bestimmung von gewebe- und/oder zelltypen zur entstehung von zellfreier dna und verfahren zur identifizierung einer krankheit oder störung damit
WO2016123698A1 (en) * 2015-02-06 2016-08-11 Uti Limited Partnership Diagnostic assay for post-transplant assessment of potential rejection of donor organs
KR101850437B1 (ko) * 2015-04-14 2018-04-20 이원다이애그노믹스(주) 차세대 염기서열 분석기법을 이용한 장기 이식 거부 반응 예측 방법
US20180142296A1 (en) * 2015-04-30 2018-05-24 Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cell-free dna
WO2016183106A1 (en) 2015-05-11 2016-11-17 Natera, Inc. Methods and compositions for determining ploidy
CN106544407B (zh) * 2015-09-18 2019-11-08 广州华大基因医学检验所有限公司 确定受体cfDNA样本中供体来源cfDNA比例的方法
CN109661475A (zh) * 2016-04-29 2019-04-19 威斯康星州立大学医学院 多重优化错配扩增(moma)靶标数目
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
WO2018085603A1 (en) * 2016-11-02 2018-05-11 Medical College Of Wisconsin, Inc. Methods for assessing risk using total and specific cell-free dna
AU2017355458A1 (en) * 2016-11-02 2019-06-13 The Medical College Of Wisconsin, Inc. Methods for assessing risk using mismatch amplification and statistical methods
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
EP3642353A4 (de) 2017-06-20 2021-02-24 The Medical College of Wisconsin, Inc. Bewertung des transplantationskomplikationsrisikos bei vollständig zellfreier dna
AU2018288838A1 (en) * 2017-06-20 2020-01-16 The Medical College Of Wisconsin, Inc. Transplant patient monitoring with cell-free DNA
JP2020526218A (ja) 2017-07-14 2020-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 移植拒絶リスクを予測する新規の方法
US20210269879A1 (en) * 2017-12-14 2021-09-02 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
US11479819B2 (en) 2017-12-15 2022-10-25 Acrannolife Genomics Pvt. Ltd. Non-invasive method for monitoring transplanted organ status in organ-transplant recipients
EP3517629A1 (de) 2018-01-30 2019-07-31 Myway Genetics S.r.L. Verwendung von cfdna-fragmenten als biomarker bei patienten nach der organtransplantation
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
US11525159B2 (en) 2018-07-03 2022-12-13 Natera, Inc. Methods for detection of donor-derived cell-free DNA
WO2020076957A1 (en) * 2018-10-09 2020-04-16 Tai Diagnostics, Inc. Cell lysis assay for cell-free dna analysis
US20220073989A1 (en) * 2018-12-20 2022-03-10 The Regents Of The University Of California Optimizing Detection of Transplant Injury by Donor-Derived Cell-Free DNA
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
CN114645077A (zh) * 2020-12-17 2022-06-21 厦门大学 一种检测受体样品中供体的存在或比例的方法和试剂盒
CN113061666A (zh) * 2020-12-30 2021-07-02 中南大学湘雅二医院 肝移植后巨细胞病毒的检测方法、应用及***
WO2023116717A1 (en) * 2021-12-22 2023-06-29 The First Affiliated Hospital Of Guangzhou Medical University Method for monitoring donar dna fraction
CN114381511A (zh) * 2021-12-31 2022-04-22 上海药明奥测医疗科技有限公司 一种评估肝移植术后移植物损伤及排斥风险的检测方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE72468B1 (en) 1987-07-31 1997-04-09 Univ Leland Stanford Junior Selective amplification of target polynucleotide sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5955589A (en) 1991-12-24 1999-09-21 Isis Pharmaceuticals Inc. Gapped 2' modified oligonucleotides
ZA918965B (en) 1990-11-13 1992-08-26 Siska Diagnostics Inc Nucleic acid amplification by two-enzyme,self-sustained sequence replication
YU187991A (sh) 1990-12-11 1994-09-09 Hoechst Aktiengesellschaft 3-(2)-amino-ali tiol-modifikovani, s fluorescentnom bojom vezani nukleozidi, nukleotidi i oligonukleotidi, postupak za njihovo dobijanje i njihova upotreba
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5652099A (en) 1992-02-12 1997-07-29 Conrad; Michael J. Probes comprising fluorescent nucleosides and uses thereof
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
DE4415370A1 (de) 1994-05-02 1995-11-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE4438918A1 (de) 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
EP0866071B1 (de) 1997-03-20 2004-10-20 F. Hoffmann-La Roche Ag Modifizierte Primer
US6440706B1 (en) 1999-08-02 2002-08-27 Johns Hopkins University Digital amplification
EP1325963B1 (de) * 2001-12-24 2006-09-27 Wolfgang Prof. Holzgreve Verfahren zur nicht-invasiven Diagnose von Transplantationen und Transfusionen
CA2677517C (en) 2007-02-08 2015-11-03 Sequenom, Inc. Nucleic acid-based tests for rhd typing, gender determination and nucleic acid quantification
CA2680588A1 (en) 2007-03-26 2008-10-02 Sequenom, Inc. Restriction endonuclease enhanced polymorphic sequence detection
US20100209926A1 (en) * 2007-09-28 2010-08-19 Stryker Corporation Methods for detecting neutralizing antibodies for bone morphogenetic proteins
US20120034603A1 (en) * 2010-08-06 2012-02-09 Tandem Diagnostics, Inc. Ligation-based detection of genetic variants
WO2012115851A1 (en) 2011-02-22 2012-08-30 City Of Hope Ultra-high sensitive monitoring of early transplantation failure
AU2013249012B2 (en) 2012-04-19 2019-03-28 The Medical College Of Wisconsin, Inc. Highly sensitive surveillance using detection of cell free DNA
EP3117012B1 (de) * 2014-03-14 2019-02-20 CareDx, Inc. Verfahren zur überwachung immunsuppressiver therapien in einem transplantatempfänger

Also Published As

Publication number Publication date
WO2014194113A2 (en) 2014-12-04
HUE041935T2 (hu) 2019-06-28
EP3004388A4 (de) 2017-01-11
US20220025459A1 (en) 2022-01-27
LT3004388T (lt) 2019-01-25
US20180346982A1 (en) 2018-12-06
EP3004388B1 (de) 2018-10-31
HRP20190209T1 (hr) 2019-04-05
ES2704682T5 (es) 2023-11-10
ES2704682T3 (es) 2019-03-19
PL3004388T3 (pl) 2019-04-30
SI3004388T2 (sl) 2023-11-30
EP3004388B2 (de) 2023-05-31
DK3004388T4 (da) 2023-08-28
US11155872B2 (en) 2021-10-26
SI3004388T1 (sl) 2019-03-29
EP3004388A2 (de) 2016-04-13
PT3004388T (pt) 2019-01-29
DK3004388T3 (en) 2019-02-04
HRP20190209T4 (hr) 2023-09-15
WO2014194113A3 (en) 2015-01-22
US20160115541A1 (en) 2016-04-28
PL3004388T5 (pl) 2023-10-09

Similar Documents

Publication Publication Date Title
CY1122332T1 (el) Ανιχνευση και ποσοτικος προσδιορισμος dna ελευθερου κυτταρων δοτη στο κυκλοφοριακο συστημα ληπτων μεταμοσχευσης οργανων
CY1123823T1 (el) Βελτιωμενες συνθεσεις τ κυτταρων
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY1122478T1 (el) Συνθεσεις που περιεχουν anti-cd38 αντισωματα και λεναλιδομιδη
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
BR112015023752A2 (pt) complexos multiespecificos monovalentes e multivalentes e seus usos
ECSP13013022A (es) Agonistas de fgfr1 y sus métodos de uso
EA201790010A1 (ru) Гамма-дельта t-клетки и их применение
EA201491574A1 (ru) Применение car, основанных на icos, для усиления противоопухолевой активности и длительного сохранения car
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
TR201900776T4 (tr) Memeli hücre kültürlerinin hasadına ilişkin yöntem.
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
EA201591740A1 (ru) Вирусы болезни ньюкасла и их применение
TR201905458T4 (tr) Fap ve dr5 için spesifik bispesifik antikorlar, dr5 için spesifik antikorlar ve bunların kullanım yöntemleri.
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
TR201910320T4 (tr) Karaciğer organoidi, kullanımları ve elde edilmesine yönelik kültür yöntemi.
UY34824A (es) Nucleósidos de espirooxetano de uracilo
BR112016015105A2 (pt) Conjugados var2csa-droga
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
CO2018013434A2 (es) Anticuerpos antifactor de la coagulación xi
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso